We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$194M
AUM Growth
+$23.9M
Cap. Flow
+$19.5M
Cap. Flow %
10.02%
Top 10 Hldgs %
62.83%
Holding
53
New
7
Increased
16
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$5.65M
2
NEOG icon
Neogen
NEOG
+$3.56M
3
ASND icon
Ascendis Pharma A/S
ASND
+$3.48M
4
VTRS icon
Viatris
VTRS
+$3.4M
5
INMD icon
InMode
INMD
+$3.13M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$9.09M
2
LNTH icon
Lantheus
LNTH
+$6.35M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.02M
4
CI icon
Cigna
CI
+$5.55M
5
BVS icon
Bioventus
BVS
+$5.25M

Sector Composition

Rank Sector Weight
1 Healthcare 69%
2 Consumer Staples 1.39%
3 Technology 0.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$453B
$39.9M 20.57%
+150,000
New +$41.5M
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
$12.6M 6.49%
715,000
+30,000
+4% +$503K
VTRS icon
3
Viatris
VTRS
$20.4B
$10.9M 5.59%
975,000
+325,000
+50% +$3.4M
SPY icon
4
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$9.56M 4.92%
25,000
+22,500
+900% +$8.65M
PHR icon
5
Phreesia
PHR
$663M
$9.22M 4.75%
285,000
+25,000
+10% +$679K
CERS icon
6
Cerus
CERS
$433M
$9.13M 4.7%
2,500,000
+75,000
+3% +$283K
COLL icon
7
Collegium Pharmaceutical
COLL
$1.15B
$8.98M 4.62%
387,000
+87,000
+29% +$1.75M
STRM
8
DELISTED
Streamline Health Solutions
STRM
$7.79M 4.01%
328,725
– –
ALKS icon
9
Alkermes
ALKS
$8.22B
$7.19M 3.7%
275,000
+75,000
+38% +$1.79M
ANGO icon
10
AngioDynamics
ANGO
$611M
$6.75M 3.47%
490,000
+165,000
+51% +$2.3M
BDX icon
11
PUT
Becton Dickinson
BDX
$45.6B
$6.36M 3.27%
25,000
+24,800
+12,400% +$5.85M
BIIB icon
12
Biogen
BIIB
$30B
$5.54M 2.85%
+20,000
New +$5.65M
ASND icon
13
Ascendis Pharma A/S
ASND
$16B
$5.5M 2.83%
45,000
+30,000
+200% +$3.48M
LNTH icon
14
Lantheus
LNTH
$6.49B
$5.35M 2.76%
105,000
-103,000
-50% -$6.35M
THC icon
15
Tenet Healthcare
THC
$20.5B
$4.64M 2.39%
95,000
-80,000
-46% -$3.7M
SIBN icon
16
SI-BONE Inc
SIBN
$788M
$4.49M 2.31%
330,000
-130,000
-28% -$1.9M
PCRX icon
17
Pacira BioSciences
PCRX
$1.04B
$3.86M 1.99%
100,000
-95,000
-49% -$4.62M
NEOG icon
18
Neogen
NEOG
$2.63B
$3.81M 1.96%
+250,000
New +$3.56M
RIGL icon
19
Rigel Pharmaceuticals
RIGL
$681M
$3.45M 1.78%
230,000
+30,000
+15% +$275K
INMD icon
20
InMode
INMD
$870M
$3.21M 1.65%
+90,000
New +$3.13M
TCMD icon
21
Tactile Systems Technology
TCMD
$635M
$2.93M 1.51%
255,000
+30,000
+13% +$264K
MRK icon
22
Merck
MRK
$322B
$2.77M 1.43%
25,000
– –
TPB icon
23
Turning Point Brands
TPB
$1.45B
$2.7M 1.39%
125,000
-40,000
-24% -$850K
DCGO icon
24
DocGo
DCGO
$64.3M
$2.65M 1.37%
375,000
– –
SNY icon
25
Sanofi
SNY
$103B
$2.42M 1.25%
50,000
-105,000
-68% -$4.61M
1
2 3

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q4 2022 Portfolio in Review

As of Q4 2022, Tamarack Advisers held 53 positions worth $194M, up 14% from $170M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Tamarack Advisers deployed $19.5M of net new capital in Q4 2022, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was Biogen: 20,000 shares worth $5.54M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 96% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Lantheus, an estimated $6.35M trimmed.

  • Tamarack Advisers's largest Q4 2022 buy was Biogen: 20,000 shares worth $5.54M.
  • Tamarack Advisers added most to Ascendis Pharma A/S in Q4 2022, an estimated $3.48M increase.
  • Tamarack Advisers's biggest Q4 2022 reduction was Lantheus, cutting an estimated $6.35M.
  • Tamarack Advisers fully exited Perrigo in Q4 2022, selling an estimated $9.09M.
  • Tamarack Advisers's ten largest holdings make up 63% of its $194M portfolio in Q4 2022.
  • Tamarack Advisers opened 7 new positions and closed 17 in Q4 2022.
  • Tamarack Advisers's portfolio value rose 14% quarter-over-quarter to $194M.

Based on Tamarack Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.